News & Updates

A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.

For adults with migraine, the drugs with the best profile include eletriptan, rizatriptan, sumatriptan, and zolmitriptan, suggests a study. These agents are more effective than most available medications on the market such as lasmiditan, rimegepant, and ubrogepant.

Interim data from the real-world TRACE study confirm the benefits of the high-affinity monoclonal antibody tralokinumab for individuals with moderate-to-severe head and neck atopic dermatitis (H&N AD) after up to 9 months of treatment.

Resistance to antipsychotic treatment may result in worse cognitive function among patients with schizophrenia, with disorganization, doses, and negative symptoms playing a major role in this association, according to a Singapore study.